Khalid Matrougui
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Khalid Matrougui has a total of 56 co-authors. Here are the top co-authors by number of shared publications:
Souad Belmadani
Eastern Virginia Medical School, Department of Physiological Sciences, 800 W Olney Rd, Norfolk, VA 23501, USA
9 shared publicationsModar Kassan
From the Department of Physiology, Hypertension and Renal Center of Excellence, Tulane University, New Orleans, LA (M.K., K.M.); Department of Physiological Sciences, EVMS, Norfolk, VA (M.K., K.A.-A., E.R., V.M., S.H., S.B., K.M.); Department of Cellular and Molecular Physiology, Penn State University College of Medicine, Hershey, PA (W.Z., M.T); and Department of Internal Medicine, University of Iowa, Iowa City (K.M., M.G., K.I.).
8 shared publicationsMohamed Trebak
Assiut University, Department of Medical Biochemistry, Faculty of Medicine, Assiut, Egypt
6 shared publications- María Galán
Department of Physiology, Hypertension and Renal Center of Excellence, Tulane University, 1430 Tulane Ave, New Orleans, LA 70112, USA
4 shared publications B. Srinivas
Department of Physiological Sciences, EVMS, Norfolk, USA
3 shared publicationsBalaji Srinivas
Department of Biomedical and Translational Sciences, Macon & Joan Brock Virginia Health Sciences at Old Dominion University, P.O. Box 1980, Norfolk, VA, 23501-1980, USA
3 shared publications
Latest Publications
- 12 March 2026
- Published by Elsevier in Translational Research
- Vol. 290, 50-60
STIM1 deletion in regulatory T cells restores redox balance and protects against hypertension-induced cardiovascular complications
- 12 March 2026
- Published by Elsevier in Translational Research
- Vol. 290, 50-60
STIM1 deletion in regulatory T cells restores redox balance and protects against hypertension-induced cardiovascular complications
- Open Access
- 22 October 2025
- Published by Elsevier in Journal of Molecular and Cellular Cardiology Plus
- Vol. 14, 100492
Deletion of CHOP in beta cell protects mice from cardiovascular complications in type 2 diabetes: evidence from a pre-clinical mouse model
- 22 October 2025
- Published by Elsevier in Journal of Molecular and Cellular Cardiology Plus
- Vol. 14, 100492
Open AccessDeletion of CHOP in beta cell protects mice from cardiovascular complications in type 2 diabetes: evidence from a pre-clinical mouse model
- Open Access
- 13 June 2025
- Published by Springer Nature in Cardiovascular Diabetology
- Vol. 24 (1) , 1-12
Novel insights into beta cell ER stress CHOP and its role in HFpEF development
Heart failure with preserved ejection fraction (HFpEF) is a multifactorial cardiovascular disorder characterized by diastolic dysfunction and often associated with hypertension and metabolic disturbances. We aimed to determine the inter-relationship between C/EBP homologous protein (CHOP) in b-cells and HFpEF development. Eight-week-old male mice b-cellflox/flox and b-cellCHOP−/− were randomly divided into four groups: control b-cellflox/flox and b-cellCHOP−/− mice subjected to standard diet and water. b -cellflox/flox and b-cellCHOP−/− mice fed a high-fat diet (HFD) and L-NAME (0.5 g/L) for five weeks. A comprehensive cardiovascular, metabolic, and histological evaluation was conducted. Following five weeks of HFD and L-NAME, b-cellflox/flox mice exhibited clinical and molecular manifestations of HFpEF. These include diastolic dysfunction, a normal cardiac ejection fraction, hypertension, metabolic disorders, cardiac hypertrophy with fibrosis, pulmonary edema, renal injury, and reduced exercise tolerance. Vascular endothelial dysfunction was also observed. Western blot analysis showed a reduced phosphorylated endothelial nitric oxide synthase in mesenteric resistance arteries (MRA), concomitant with qRT-PCR data revealing elevated inflammatory and unfolded protein response markers in MRA, heart, and pancreas. Interestingly, b-cellCHOP−/− mice subjected to an HFD and L-NAME were protected from HFpEF and its associated pathologies. These mice displayed improved cardiac and vascular endothelial function, exercise tolerance, and reduced unfolded protein response and inflammatory factors compared to their b-cellflox/flox. Our research indicates that deleting the unfolded protein response CHOP in b-cells has a robust cardiovascular protective effect against HFpEF pathogenesis. Therefore, targeting CHOP in b-cells is a promising lead for HFpEF pathogenesis therapy.
- 13 June 2025
- Published by Springer Nature in Cardiovascular Diabetology
- Vol. 24 (1) , 1-12
Open AccessNovel insights into beta cell ER stress CHOP and its role in HFpEF development
Heart failure with preserved ejection fraction (HFpEF) is a multifactorial cardiovascular disorder characterized by diastolic dysfunction and often associated with hypertension and metabolic disturbances. We aimed to determine the inter-relationship between C/EBP homologous protein (CHOP) in b-cells and HFpEF development. Eight-week-old male mice b-cellflox/flox and b-cellCHOP−/− were randomly divided into four groups: control b-cellflox/flox and b-cellCHOP−/− mice subjected to standard diet and water. b -cellflox/flox and b-cellCHOP−/− mice fed a high-fat diet (HFD) and L-NAME (0.5 g/L) for five weeks. A comprehensive cardiovascular, metabolic, and histological evaluation was conducted. Following five weeks of HFD and L-NAME, b-cellflox/flox mice exhibited clinical and molecular manifestations of HFpEF. These include diastolic dysfunction, a normal cardiac ejection fraction, hypertension, metabolic disorders, cardiac hypertrophy with fibrosis, pulmonary edema, renal injury, and reduced exercise tolerance. Vascular endothelial dysfunction was also observed. Western blot analysis showed a reduced phosphorylated endothelial nitric oxide synthase in mesenteric resistance arteries (MRA), concomitant with qRT-PCR data revealing elevated inflammatory and unfolded protein response markers in MRA, heart, and pancreas. Interestingly, b-cellCHOP−/− mice subjected to an HFD and L-NAME were protected from HFpEF and its associated pathologies. These mice displayed improved cardiac and vascular endothelial function, exercise tolerance, and reduced unfolded protein response and inflammatory factors compared to their b-cellflox/flox. Our research indicates that deleting the unfolded protein response CHOP in b-cells has a robust cardiovascular protective effect against HFpEF pathogenesis. Therefore, targeting CHOP in b-cells is a promising lead for HFpEF pathogenesis therapy.
- Open Access
- 13 June 2025
- Published by Springer Nature in Cellular and Molecular Life Sciences
- Vol. 82 (1) , 1-14
Endothelial CHOP as a central mechanism in renovascular hypertension-induced vascular endothelial dysfunction and cardiac fibrosis
Objective In this study, we sought to determine the significant impact of the vascular endothelial endoplasmic reticulum (ER) stress C/EBP homologous protein (CHOP) in renovascular hypertension-induced vascular endothelial dysfunction and cardiac fibrosis. Approach and results Eight-week-old male and female CHOPflox/flox and ECCHOP−/− mice were randomly divided into eight groups with and without 2-Kidney-1-Clip (2K1C) surgery for four weeks. Body weight, systolic blood pressure, running performance, cardiac hypertrophy and fibrosis, lung edema, inflammation, vascular endothelial function, and signaling were assessed. For the mechanism, we utilized human coronary endothelial cells, both with and without CHOP down-regulation, and then stimulated them with and without angiotensin II ± ATP to determine eNOS phosphorylation level and the presence of inflammatory factors. Male and female CHOPflox/flox mice subjected to 2K1C for four weeks exhibited hypertension, cardiac hypertrophy and fibrosis, lung edema, impaired running performance, endothelium-dependent vascular relaxation dysfunction, reduction in eNOS phosphorylation, and inflammation induction. In contrast, male and female ECCHOP−/− mice subjected to 2K1C for four weeks were protected against the pathogenesis of renovascular hypertension. In vitro, data showed that deletion of CHOP in endothelial cells protected eNOS phosphorylation level and blunted the induction of inflammation in response to angiotensin II ± ATP. Conclusion Our research findings determined that CHOP is a central mechanism driving vascular endothelial dysfunction and cardiac fibrosis in renovascular hypertension. Therefore, targeting CHOP in endothelial cells could be a potential therapeutic approach to protect against the pathogenesis of renovascular hypertension.
- 13 June 2025
- Published by Springer Nature in Cellular and Molecular Life Sciences
- Vol. 82 (1) , 1-14
Open AccessEndothelial CHOP as a central mechanism in renovascular hypertension-induced vascular endothelial dysfunction and cardiac fibrosis
Objective In this study, we sought to determine the significant impact of the vascular endothelial endoplasmic reticulum (ER) stress C/EBP homologous protein (CHOP) in renovascular hypertension-induced vascular endothelial dysfunction and cardiac fibrosis. Approach and results Eight-week-old male and female CHOPflox/flox and ECCHOP−/− mice were randomly divided into eight groups with and without 2-Kidney-1-Clip (2K1C) surgery for four weeks. Body weight, systolic blood pressure, running performance, cardiac hypertrophy and fibrosis, lung edema, inflammation, vascular endothelial function, and signaling were assessed. For the mechanism, we utilized human coronary endothelial cells, both with and without CHOP down-regulation, and then stimulated them with and without angiotensin II ± ATP to determine eNOS phosphorylation level and the presence of inflammatory factors. Male and female CHOPflox/flox mice subjected to 2K1C for four weeks exhibited hypertension, cardiac hypertrophy and fibrosis, lung edema, impaired running performance, endothelium-dependent vascular relaxation dysfunction, reduction in eNOS phosphorylation, and inflammation induction. In contrast, male and female ECCHOP−/− mice subjected to 2K1C for four weeks were protected against the pathogenesis of renovascular hypertension. In vitro, data showed that deletion of CHOP in endothelial cells protected eNOS phosphorylation level and blunted the induction of inflammation in response to angiotensin II ± ATP. Conclusion Our research findings determined that CHOP is a central mechanism driving vascular endothelial dysfunction and cardiac fibrosis in renovascular hypertension. Therefore, targeting CHOP in endothelial cells could be a potential therapeutic approach to protect against the pathogenesis of renovascular hypertension.
- Open Access
Role of plasmacytoid dendritic cells in vascular dysfunction in mice with renovascular hypertension
- Open Access
- 12 January 2024
- Published by Elsevier in Journal of Molecular and Cellular Cardiology Plus
- Vol. 7
Unveiling the vulnerability of C57BL/6J female mice to HFpEF and its related complications
- 12 January 2024
- Published by Elsevier in Journal of Molecular and Cellular Cardiology Plus
- Vol. 7
Open AccessUnveiling the vulnerability of C57BL/6J female mice to HFpEF and its related complications
- Open Access
- 29 November 2023
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 10, 1222243
Plasmacytoid dendritic cells contribute to vascular endothelial dysfunction in type 2 diabetes
Objective: Type 2 diabetes (T2D) is associated with an increased risk of cardiovascular disease due to macro- and microvascular dysfunction. This study aimed to investigate the potential involvement of plasmacytoid dendritic cells (pDCs) in T2D-related vascular dysfunction.Approach and results: pDCs were isolated from db/db and control mice. It was found that pDCs from db/db mice impaired endothelial cell eNOS phosphorylation in response to ATP and decreased vascular endothelium-dependent relaxation compared to pDCs from control mice. Moreover, isolated CD4+ cells from control mice, when stimulated overnight with high glucose and lipids, and isolated pDCs from db/db mice, display elevated levels of ER stress, inflammation, and apoptosis markers. Flow cytometry revealed that pDC frequency was higher in db/db mice than in controls. In vivo, the reduction of pDCs using anti-PDCA-1 antibodies in male and female db/db mice for 4 weeks significantly improved vascular endothelial function and eNOS phosphorylation.Conclusion: pDCs may contribute to vascular dysfunction in T2D by impairing endothelial cell function. Targeting pDCs with anti-PDCA-1 antibodies may represent a promising therapeutic strategy for improving vascular endothelial function in T2D patients. This study provides new insights into the pathogenesis of T2D-related vascular dysfunction and highlights the potential of immunomodulatory therapies for treating this complication. Further studies are warranted to explore the clinical potential of this approach.
- 29 November 2023
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 10, 1222243
Open AccessPlasmacytoid dendritic cells contribute to vascular endothelial dysfunction in type 2 diabetes
Objective: Type 2 diabetes (T2D) is associated with an increased risk of cardiovascular disease due to macro- and microvascular dysfunction. This study aimed to investigate the potential involvement of plasmacytoid dendritic cells (pDCs) in T2D-related vascular dysfunction.Approach and results: pDCs were isolated from db/db and control mice. It was found that pDCs from db/db mice impaired endothelial cell eNOS phosphorylation in response to ATP and decreased vascular endothelium-dependent relaxation compared to pDCs from control mice. Moreover, isolated CD4+ cells from control mice, when stimulated overnight with high glucose and lipids, and isolated pDCs from db/db mice, display elevated levels of ER stress, inflammation, and apoptosis markers. Flow cytometry revealed that pDC frequency was higher in db/db mice than in controls. In vivo, the reduction of pDCs using anti-PDCA-1 antibodies in male and female db/db mice for 4 weeks significantly improved vascular endothelial function and eNOS phosphorylation.Conclusion: pDCs may contribute to vascular dysfunction in T2D by impairing endothelial cell function. Targeting pDCs with anti-PDCA-1 antibodies may represent a promising therapeutic strategy for improving vascular endothelial function in T2D patients. This study provides new insights into the pathogenesis of T2D-related vascular dysfunction and highlights the potential of immunomodulatory therapies for treating this complication. Further studies are warranted to explore the clinical potential of this approach.
- Open Access
- 18 July 2023
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 12 (14) , e029668
Interleukin‐1β Disruption Protects Male Mice From Heart Failure With Preserved Ejection Fraction Pathogenesis
Background: Heart failure with preserved ejection fraction (HFpEF) is a significant unmet need in cardiovascular medicine and remains an untreatable cardiovascular disease. The role and mechanism of interleukin‐1β in HFpEF pathogenesis are poorly understood. Methods and Results: C57/Bl6J and interleukin‐1β −/− male mice were randomly divided into 4 groups. Groups 1 and 2: C57/Bl6J and interleukin‐1β −/− mice were fed a regular diet for 4 months and considered controls. Groups 3 and 4: C57/Bl6 and interleukin‐1β −/− mice were fed a high‐fat diet with N[w]‐nitro‐l‐arginine methyl ester (endothelial nitric oxide synthase inhibitor, 0.5 g/L) in the drinking water for 4 months. We measured body weight, blood pressure, diabetes status, cardiac function/hypertrophy/inflammation, fibrosis, vascular endothelial function, and signaling. C57/Bl6 fed a high‐fat diet and N[w]‐nitro‐l‐arginine methyl ester in the drinking water for 4 months developed HFpEF pathogenesis characterized by obesity, diabetes, hypertension, cardiac hypertrophy, lung edema, low running performance, macrovascular and microvascular endothelial dysfunction, and diastolic cardiac dysfunction but no change in cardiac ejection fraction compared with control mice. Interestingly, the genetic disruption of interleukin‐1β protected mice from HFpEF pathogenesis through the modulation of the inflammation and endoplasmic reticulum stress mechanisms. Conclusions: Our data suggest that interleukin‐1β is a critical driver in the development of HFpEF pathogenesis, likely through regulating inflammation and endoplasmic reticulum stress pathways. Our findings provide a potential therapeutic target for HFpEF treatment.
- 18 July 2023
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 12 (14) , e029668
Open AccessInterleukin‐1β Disruption Protects Male Mice From Heart Failure With Preserved Ejection Fraction Pathogenesis
Background: Heart failure with preserved ejection fraction (HFpEF) is a significant unmet need in cardiovascular medicine and remains an untreatable cardiovascular disease. The role and mechanism of interleukin‐1β in HFpEF pathogenesis are poorly understood. Methods and Results: C57/Bl6J and interleukin‐1β −/− male mice were randomly divided into 4 groups. Groups 1 and 2: C57/Bl6J and interleukin‐1β −/− mice were fed a regular diet for 4 months and considered controls. Groups 3 and 4: C57/Bl6 and interleukin‐1β −/− mice were fed a high‐fat diet with N[w]‐nitro‐l‐arginine methyl ester (endothelial nitric oxide synthase inhibitor, 0.5 g/L) in the drinking water for 4 months. We measured body weight, blood pressure, diabetes status, cardiac function/hypertrophy/inflammation, fibrosis, vascular endothelial function, and signaling. C57/Bl6 fed a high‐fat diet and N[w]‐nitro‐l‐arginine methyl ester in the drinking water for 4 months developed HFpEF pathogenesis characterized by obesity, diabetes, hypertension, cardiac hypertrophy, lung edema, low running performance, macrovascular and microvascular endothelial dysfunction, and diastolic cardiac dysfunction but no change in cardiac ejection fraction compared with control mice. Interestingly, the genetic disruption of interleukin‐1β protected mice from HFpEF pathogenesis through the modulation of the inflammation and endoplasmic reticulum stress mechanisms. Conclusions: Our data suggest that interleukin‐1β is a critical driver in the development of HFpEF pathogenesis, likely through regulating inflammation and endoplasmic reticulum stress pathways. Our findings provide a potential therapeutic target for HFpEF treatment.
- Open Access
- 30 August 2022
- Published by Taylor & Francis in Diabetes, Metabolic Syndrome and Obesity
- Vol. ume 15, 2633-2642
Disrupting Interleukin 12 Improves Microvascular Endothelial Function in Type 2 Diabetes Through ER Stress CHOP and Oxidative Stress Mechanisms
Purpose: Vascular endothelial dysfunction is well established in type 2 diabetes. Interleukin-12 (IL-12) and endoplasmic reticulum (ER) stress are up-regulated in type 2 diabetic patients and animal models of type 2 diabetes. However, the role and underlying mechanisms of IL-12 and the ER stress CHOP in endothelial dysfunction are not fully understood. Methods: We generated double knockout mice between db−/db− and p40IL-12−/− mice (db−/db−p40-IL− 12-/-) and endoplasmic (ER) stress-CHOP−/− mice (db−/db−CHOP-/-). We performed a glucose tolerance test (GTT) to determine the effect of IL-12 and ER stress CHOP on glucose metabolism. We assessed the endothelial function and determined the phosphorylation level of eNOS, Akt, AMPK, and the expression of ER stress (CHOP, BIP), and oxidative stress (Nox2 and Nox4 and NADPH oxidase activity). Results: The results showed that GTT was improved in db-/db−p40-IL− 12-/- and db−/db−CHOP-/- suggesting IL-12 and CHOP as parts of a mechanism involved in the development of type 2 diabetes. The microvascular endothelial dysfunction in db−/db− mouse is associated with decreased phosphorylated eNOS, Akt, AMPK, and increased CHOP, BIP, Nox2, and Nox4 expressions. Interestingly, disrupting IL-12 and ER stress CHOP in db−/db− mice significantly improved endothelial function, increased survival markers expression and decreased ER and oxidative stress. Conclusion: Using a genetic approach, these findings provide evidence that IL-12 and ER stress CHOP play a significant role in microvascular endothelial dysfunction in type 2 diabetes.
- 30 August 2022
- Published by Taylor & Francis in Diabetes, Metabolic Syndrome and Obesity
- Vol. ume 15, 2633-2642
Open AccessDisrupting Interleukin 12 Improves Microvascular Endothelial Function in Type 2 Diabetes Through ER Stress CHOP and Oxidative Stress Mechanisms
Purpose: Vascular endothelial dysfunction is well established in type 2 diabetes. Interleukin-12 (IL-12) and endoplasmic reticulum (ER) stress are up-regulated in type 2 diabetic patients and animal models of type 2 diabetes. However, the role and underlying mechanisms of IL-12 and the ER stress CHOP in endothelial dysfunction are not fully understood. Methods: We generated double knockout mice between db−/db− and p40IL-12−/− mice (db−/db−p40-IL− 12-/-) and endoplasmic (ER) stress-CHOP−/− mice (db−/db−CHOP-/-). We performed a glucose tolerance test (GTT) to determine the effect of IL-12 and ER stress CHOP on glucose metabolism. We assessed the endothelial function and determined the phosphorylation level of eNOS, Akt, AMPK, and the expression of ER stress (CHOP, BIP), and oxidative stress (Nox2 and Nox4 and NADPH oxidase activity). Results: The results showed that GTT was improved in db-/db−p40-IL− 12-/- and db−/db−CHOP-/- suggesting IL-12 and CHOP as parts of a mechanism involved in the development of type 2 diabetes. The microvascular endothelial dysfunction in db−/db− mouse is associated with decreased phosphorylated eNOS, Akt, AMPK, and increased CHOP, BIP, Nox2, and Nox4 expressions. Interestingly, disrupting IL-12 and ER stress CHOP in db−/db− mice significantly improved endothelial function, increased survival markers expression and decreased ER and oxidative stress. Conclusion: Using a genetic approach, these findings provide evidence that IL-12 and ER stress CHOP play a significant role in microvascular endothelial dysfunction in type 2 diabetes.
- 7 April 2022
- Published by Springer Nature in Inflammation
- Vol. 45 (5) , 1864-1874
Role of High Mobility Group Box 1 in Cardiovascular Diseases
High Mobility Group Box 1 (HMGB1) is a ubiquitous, highly conserved nuclear and cytosolic protein that has diverse biological roles depending on its cellular location and posttranslational modifications. The HMGB1 is localized in the nucleus but can be translocated to the cytoplasm to modulate the intracellular signaling and eventually secreted outside the cells. It is widely established that HMGB1 plays a key role in inflammation; however, the role of HMGB1 in the cardiovascular diseases is not well understood. In this review, we will discuss the latest reports on the pathophysiological link between HMGB1 and cardiovascular complications, with special emphasis on the inflammation. Thus, the understanding of the role of HMGB1 may provide new insights into developing new HMGB1-based therapies.
- 7 April 2022
- Published by Springer Nature in Inflammation
- Vol. 45 (5) , 1864-1874
Role of High Mobility Group Box 1 in Cardiovascular Diseases
High Mobility Group Box 1 (HMGB1) is a ubiquitous, highly conserved nuclear and cytosolic protein that has diverse biological roles depending on its cellular location and posttranslational modifications. The HMGB1 is localized in the nucleus but can be translocated to the cytoplasm to modulate the intracellular signaling and eventually secreted outside the cells. It is widely established that HMGB1 plays a key role in inflammation; however, the role of HMGB1 in the cardiovascular diseases is not well understood. In this review, we will discuss the latest reports on the pathophysiological link between HMGB1 and cardiovascular complications, with special emphasis on the inflammation. Thus, the understanding of the role of HMGB1 may provide new insights into developing new HMGB1-based therapies.